Supports
Healthy Prostate
In a randomized, double-blind,
placebo-controlled, multicenter study of 200 men with benign
prostate enlargement, half the group received 180 mg of beta-sitosterol
daily, while the other half received placebo. After six months,
the beta-sitosterol group saw improvement in the International
Prostate Symptom Score, the measurement of urine flow (QMax),
and the amount of residual urine remaining in the bladder
(PUR).
The beta-sitosterol group showed
a 7.4-point decrease in the International Prostate Symptom
Score, compared to a decrease of only 2.1 points in the
placebo group . . . a significant 3.5-fold improvement in
the men taking beta-sitosterol.
The measurement of urinary
flow increased to an average of 15.2 milliliters (ml) per
second from 9.9 ml/second in the men receiving beta-sitosterol.
The placebo group only increased to 11.4 ml/second from
10.2 ml/second at baseline. Urinary flow thus improved almost
35% in the group taking beta-sitosterol, compared to only
11% in the placebo group.
Most remarkably, residual urine
in the bladder decreased to 30.4 ml from 65.8 ml in the
men using beta-sitosterol . . . a reduction of almost 54%!
In the placebo group, residual bladder urine declined from
64.8 ml to 54.3 ml . . . a reduction of only around 16%.
|
